San Diego, CA -- (SBWIRE) -- 11/17/2015 -- An investigation for shareholders in Arena Pharmaceuticals shares concerning possible securities laws violations by Arena Pharmaceuticals in connection certain financial statements was announced.

Investors who purchased shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) concerning whether a series of statements by Arena Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On August 5, 2015, Arena Pharmaceuticals, Inc reported its second quarter 2015 financial results and provided a corporate update. Arena Pharmaceuticals, Inc reported that its second quarter Total Revenue declined from $12.80 million in 2014 to $9.18 million in 2015 ad that its second quarter 2014 Net income of $7.48 million declined to a second quarter 2015 Net Loss of $26.81 million.

On October 5, 2015, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that, at the request of the Board of Directors, Jack Lief, Arena Pharmaceuticals' President and Chief Executive Officer, has retired from the company, including its Board of Directors. Arena Pharmaceuticals, Inc. also reported that it is conducting an ongoing evaluation of its programs and operations, and intends to provide details regarding its 2016 financial plan later this year.

On November 16, 2105, NASDAQ:ARNA shares closed at $1.70 per share.

Those who purchased Arena Pharmaceuticals shares have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com